

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
9 February 2012 (09.02.2012)

PCT

(10) International Publication Number  
WO 2012/017449 A1


- (51) International Patent Classification:  
C07D 498/18 (2006.01) A61P 41/00 (2006.01)  
A61K 31/436 (2006.01)
- (21) International Application Number:  
PCT/IN2011/000508
- (22) International Filing Date:  
2 August 2011 (02.08.2011)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
299/MUM/2010 4 August 2010 (04.08.2010) IN
- (71) Applicant (for all designated States except US): MERIL LIFE SCIENCES PVT. LTD [IN/IN]; Near G. M. Bilakhia Stadium, Muktanand Marg, Chala, Vapi 396 191, Gujarat (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): RANE, Dhananjay, Sharad [IN/IN]; A/6, Shubhechaa CHS, S.V. Road, Bhaskar Colony, Naupada, Thane (W) 400 602, Maharashtra (IN). VYAS, Rajnikant, Gandadal [IN/IN]; B/602, Eternia, Main Street, Hiranandani Gardens, Powai,

Mumbai 400 076, Maharashtra (IN). MINOCHA, Pramod, Kumar [IN/IN]; Tapsya, Bhagyoday Society, Daman Road, Chala, Vapi 396 191, Gujarat (IN).

- (74) Agent: SREE, Aruna, P.; Patent & Trademark Attorney, Gopakumar Nair Associates, 3rd Floor, 'Shivmangal', Near Big Bazaar, Akurli Road, Kandivali (East), Mumbai 400 101, Maharashtra (IN).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: PROCESS FOR PREPARATION OF NOVEL 42-0-(HETEROALKOXYALKYL) RAPAMYCIN COMPOUNDS WITH ANTI-PROLIFERATIVE PROPERTIES"



(57) Abstract: The invention discloses novel 42-0-(heteroalkoxyalkyl) rapamycin compounds of formula (1) and process for preparation thereof. These compounds are useful in the treatment of hyperproliferative vascular diseases such as restenosis and atherosclerosis Wherein, R denotes 3, 4 and 5 membered 3-hydroxy heteroalkoxyalkyl compounds selected from Tetrahydrofuran-3-ol, Oxetan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-4-methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2,5-diethyl-2-methyl furan-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol.

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,  
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

— of inventorship (Rule 4.17(iv))

**Published:**

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

**“PROCESS FOR PREPARATION OF NOVEL 42-O-(HETEROALKOXYALKYL)  
RAPAMYCIN COMPOUNDS WITH ANTI-PROLIFERATIVE PROPERTIES”**

**FIELD OF THE INVENTION:**

This invention is directed to novel 42-O-(heteroalkoxyalkyl) rapamycins as well as their methods for making, their biocompatibility and anti-proliferative properties.

**BACKGROUND OF THE INVENTION:**

On reviewing of literature on rapamycin and some of its derivatives; specifically used for controlling restenosis treatment, we found that the control of the restenosis after percutaneous transluminal coronary angioplasty (PTCA) still remains one of the most important limitations. Despite of early success, the occurrence of restenosis after initial PTCA is between 30 and 50%, however later years it is reduced to 20-30%, (Hamon, M. et al., Drug Therapy, 4: 291-301 (1998); Bauters C. et al., European Heart Journal, 16: 3348 (1995)). Neo-intimal hyperplasia and vascular remodelling are two major component processes considered for restenosis after PTCA, the former coming initially, the latter occurring later in the process (Hoffman, R. et al., Circulation, 94: 1247-1254 (1996); Oesterle, S. et al., American Heart Journal, 136: 578-599 (1998), Kenneth G. et al., Journal of the American collage of cardiology, 35: 583-591 (2000)).

With use of vascular remodelling process control approach, one should eliminate or reduce restenosis. This can be skilfully done by implanting a metal stent in the stenosed lumen of the arterial vessel after PTCA procedure. Coronary stents are tiny tubular scaffolds which are widely used to prevent acute reclosure or collapse of weakened vessels following angioplasty procedure. Stents are now regularly implanted in 70 to 80% of all interventional cases (Emanuele B. et Al., European Heart Journal, 24: 394-403 (2003), Schluter L. et al., Kardiovask Med., 7: 61-70 (2005)).

Despite of this success, the problem of restenosis is yet to be completely understood or conquered (Hamon, M. et al., Drug Therapy, 4: 291-301 (1998); Oesterle, S. et al., American Heart Journal, 136: 578-599 (1998)) The injury in target vessel during balloon

angioplasty and stent implantation procedure often induce excessive healing response, including thrombosis and cell proliferation, which eventually leads to the in-stent restenosis. There remains a need to solve the eventual renarrowing of the lumen inside the stent (i.e. restenosis) after angioplasty and stent placement experienced by many patients ((Lally C. et al., .Wiley Encyclopedia of Biomedical Engineering 2006); (Peter J. et al., Rev. Esp. Cardiol. 61: 1001-1006 (2008))).

This problem is addressed by the use of antiproliferative drugs like paclitaxel, rapamycin and its analogues as mentioned in various publications. The family of paclitaxel drug in general has cytotoxic properties hence it has limited application in the use of drug eluting stents. On the other hand drug rapamycin and its analogues are widely used for this application being non-cytotoxic (cytostatic) in nature.

In an effort to increase the potency or specificity of pharmacological action till date various structural features of rapamycin have been modified. We found number of U.S. patents such as U.S. Patent No. 7,220,755 discloses 42-O-alkoxyalkyl rapamycin derivatives and composition comprising same, U.S. Patent. No. 2009/0209572 discloses 36-DES(3-Methoxy-4-Hydroxycyclohexyl) 36-(3-Hydroxycycloheptyl) derivatives of rapamycin, U.S. Patent. No. 7,812,155 B2 discloses process for preparing an O-alkylated Rapamycin derivatives having normal stereochemistry at the 42 position. The PCI published application 2010/0249415 A1 discloses process for preparation of Temsirolimus.


Some chemical modifications of rapamycin have been attempted in recent years. These include the preparation of O-alkylated rapamycin derivatives by Masashi Isozaki in U.S. Patent 7,193,078 B2, March 2007; Pimecrolimus a rapamycin derivative by Viktor Gyollai in U.S. Patent 7,279,571 B2, Oct. 2007; Tetrazole derivatives of rapamycin by Madhup Dhaon in U.S. Patent 2010/0204466 A1, Aug 2010 and Alkyl benzene sulfonate rapamycin derivatives by Kwang-Chung Lee in U.S. Patent 7,872,122 B2, Jan. 2011. However, these attempts were limited to manufacturing process and no further potency study of these derivatives completed. Therefore, there remains unmet need for rapamycin derivatives with improved anti-proliferative properties.

Accordingly, the object of the invention is to provide novel compounds of rapamycin which are useful as an anti-proliferative agents possessing the general structure of rapamycin wherein, the hydroxyl group in the 42-position has been modified to corresponding 42-O-(heteroalkoxyalkyl) rapamycin compounds and methods for preparing the same.

#### SUMMARY OF THE INVENTION:

In accordance with the above objective, the invention provides novel compounds of rapamycin wherein, the hydroxyl group in the 42-position has been modified to corresponding 42-O-(heteroalkoxyalkyl) rapamycin compounds and methods for preparing the same.

According to one aspect, the invention provides novel 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1.



Wherein, R denotes 3, 4 and 5 membered 3-hydroxy heteroalkoxyalkyl compounds Tetrahydrofuran-3-ol, Oxetan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-4-methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2,5-diethyl-2-methyl furan-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol.

Accordingly, in one preferred embodiment, R is tetrahydrofuran-3-yl to arrive at 42-O-(tetrahydrofuran-3-yl) rapamycin compound, designated herein as Merilimus-1.

In another preferred embodiment, R is oxetan-3-yl to arrive at 42-O-(oxetan-3-yl) rapamycin compound, designated herein as Merilimus-2.

In yet another preferred embodiment, R is tetrahydropyran-3-yl to arrive at 42-O-(tetrahydropyran-3-yl) rapamycin compound, designated herein as Merilimus-3.

In another embodiment, R is 3-Furanol, tetrahydro-4-methyl- to arrive at 42-O-(4-methyl, tetrahydrofuran-3-yl) rapamycin compound.

In yet another embodiment, R is 3-Furanol, tetrahydro-2,5,5-trimethyl- to arrive 42-O-(2,5,5-trimethyl, tetrahydrofuran-3-yl) rapamycin compound.

In another embodiment, R is 3-Furanol, Tetrahydro-2, 5-Diethyl-2-Methyl- to arrive at 42-O-(2,5-diethyl-2-methyl, tetrahydrofuran-3-yl) rapamycin compound.

In yet another embodiment, R is 2H-Pyran-3-yl, tetrahydro-6-methoxy-2-methyl- to arrive at 42-O-(2H-Pyran-3-yl, tetrahydro-6-methoxy-2-methyl) rapamycin compound.

In yet another embodiment, R is 2H-Pyran-3-yl, tetrahydro-2, 2-dimethyl-6-phenyl- to arrive at 42-O-(2H-Pyran-3-yl, tetrahydro-2,2-dimethyl-6-phenyl) rapamycin compound.

According to another aspect, the present invention provides a method for making 42-O-(heteroalkoxyalkyl) rapamycin compounds by reacting rapamycin with triflic (trifluoromethanesulfonic) anhydride to prepare triflate intermediate which further on reaction with 3-hydroxy heteroalkoxyalkyl compound yields desired compounds. The details of the synthesis are exemplified below.

Accordingly, the method for making 42-O-(heteroalkoxyalkyl) rapamycin compounds represented by the general formula (1), comprises reaction of rapamycin with triflic

anhydride in presence of an organic base and halogenated organic solvent to prepare triflate intermediate which further on reaction with 4, 5 or 6- membered 3-hydroxy heteroalkoxyalkyl compound in presence of trialkyl amine and inert organic solvent yields 42-O-(heteroalkoxyalkyl) rapamycin compounds..

The organic base according to the invention may be selected from pyridine or its derivatives. The pyridine derivative is preferably 2, 6 dimethyl pyridine, which is used in amount of 3 to 15 mol per mol of rapamycin.

The triflic anhydride is used in an amount of 1 to 10 mol per mol of the 42-O-(heteroalkoxyalkyl) rapamycin compounds.

The inert organic solvent is selected from halogenated organic solvent, which is used in an amount of 10 to 30 parts by weight for 1 part by weight of rapamycin.

The halogenated organic solvent is selected from the group consisting of methylene chloride, ethylene dichloride, chlorobenzene or chloroform.

The trialkyl amine is selected from triethyl amine, N, N-Di-isopropylethylamine or N, N-Di-n-butylethylamine and is used in the reaction in an amount of 5 to 20 mol per mol of rapamycin.

The 3-hydroxy heteroalkoxyalkyl compound for the purpose of the invention is selected from Oxetan-3-ol, Tetrahydrofuran-3-ol, Tetrahydro-4-methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2, 5-diethyl-2-methyl furan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol.

The 3-hydroxy heteroalkoxyalkyl compound is used in the reaction in an amount of 1 to 7 mol per mol of rapamycin.

The crude 42-O-(heteroalkoxyalkyl) rapamycin compounds obtained according to the method of invention is purified by two stage purification by preparative HPLC using two different columns.

The first stage of purification is done by preparative HPLC in an amount of 5 to 25 parts by weight for 1 part by weight of the crude 42-O-(heteroalkoxyalkyl) rapamycin compound followed by passing through second stage of column purification to get 42-O-(heteroalkoxyalkyl) rapamycin compound with purity of at least about 95% area by HPLC, more preferably at least about 98% area by HPLC.

The 42-O-(heteroalkoxyalkyl) rapamycin compound obtained according to the process of present invention is further stabilized by the addition of an anti-oxidant for enhancing a storage stability of 42-O-(heteroalkoxyalkyl) rapamycin compounds.

The preferable anti-oxidant is selected from butylated hydroxy toluene (BHT), DL- $\alpha$ -tocopherol, propyl gallate, ascorbyl palmitate, 3-tert-butyl-4-hydroxyanisole, 2-tert-butyl-4-hydroxyanisole, and fumaric acid.

The anti-oxidant as used is 0.1% to 1.0% (w/w) based on 100% (w/w) of said 42-O-(heteroalkoxyalkyl) rapamycin compound.

In a further aspect, 42-O-(heteroalkoxyalkyl) rapamycin compounds prepared according to the invention are tested for their biological activities like, haemocompatibility, haemolysis and cytotoxicity. The potency of 42-O-(heteroalkoxyalkyl) rapamycin compounds also assessed for anti-proliferation effect in comparison with rapamycin.

In yet another aspect, the invention provides pharmaceutical compositions comprising 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 in association with one or more pharmaceutical carrier/excipients. The pharmaceutical compositions incorporating 42-O-(heteroalkoxyalkyl) rapamycin compounds can be prepared into various formulations for achieving desired therapeutic/clinical effect. Methods of making such formulations are well known in the art, where the active ingredient is mixed with suitable pharmaceutical excipient/carrier to yield desired formulation suitable for oral, injectable, parenteral, local administration or coating on implantable medical devices.

In yet another aspect, the invention provides method of preventing or treating hyperproliferative vascular disease selected from the group consisting of restenosis and vascular occlusion in a mammal by administering compound of formula 1 in association with one or more pharmaceutical carriers to said subject orally, parenterally, intravascularly, or via an implantable medical device impregnated with the compound of Formula 1 in association with one or more pharmaceutical carriers.

In yet another aspect, the invention provides method of preventing or treating arterial restenosis in a mammal by implanting a medical device coated with an effective amount of 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 in association with one or more pharmaceutical carriers.

In a further aspect, the invention provides use of 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 for the preparation of medicament for the treatment of hyperproliferative vascular disease.

In a further aspect, the invention provides use of 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 for coating on implantable medical device for the treatment of arterial restenosis.

**Description of drawings:**

FIG 1A shows thermal effect on stability of various 42-O-(heteroalkoxyalkyl) rapamycin compounds without BHT at 40 °C Temperature up to 12 weeks period.

FIG 1B shows effect of anti-oxidant (1% BHT) on stability of various 42-O-(heteroalkoxyalkyl) rapamycin compounds at 40 °C temperature up to 8 weeks period.


FIG 2A shows a plot showing in-vitro cellular proliferation assay of human smooth muscle cells in-vitro, expressed as the percentage of growth relative to control cells, as a function of molar drug concentration of 42-O-(Oxetan-3-yl) rapamycin and 42-O-(tetrahydrofuran-3-yl) rapamycin compounds.

FIG 2B shows a plot showing in-vitro cellular proliferation of Rabbit Iliac smooth muscle cells in-vitro, expressed as the percentage of growth relative to control cells, as a function of molar drug concentration of 42-O-(oxetan-3-yl) rapamycin and 42-O-(tetrahydrofuran-3-yl) rapamycin Compounds.

**DETAIL DESCRIPTION OF THE INVENTION:**

The invention will now be described in detail in connection with certain preferred and optional embodiments, so that various aspects thereof may be more fully understood and appreciated.

Accordingly, the present invention discloses 42-O-(heteroalkoxyalkyl) rapamycin compounds of general structural formula (1) and chemical method for making purified 42-O-(heteroalkoxyalkyl) rapamycin compounds.




Wherein, R denotes 3, 4 and 5 membered 3-hydroxy heteroalkoxyalkyl compounds selected from Tetrahydrofuran-3-ol, Oxetan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-4-methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2,5-diethyl-2-methyl furan-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol.

Accordingly, the present invention encompasses the following compounds of 42-O-(heteroalkoxyalkyl) rapamycin of formulas (8) to (15).

1. Tetrahydrofuran-3-yl compound


Formula (8)



42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1)

2. 4-methyl, tetrahydrofuran-3-yl compound


Formula (9)



42-O-(4-methyl, tetrahydrofuran-3-yl) rapamycin

3. 2,5,5-trimethyl, tetrahydrofuran-3-ol compound


Formula (10)



42-O-(2,5,5-trimethyl, tetrahydrofuran-3-yl) rapamycin

4. 2,5-diethyl-2-methyl, tetrahydrofuran-3-ol compound


Formula (11)



42-O-(2,5-diethyl-2-methyl, tetrahydrofuran-3-yl) rapamycin

5. Oxetan-3-ol compound


Formula (12)



42-O-(oxetan-3-yl) rapamycin (Merilimus-2)

## 6. Tetrahydropyran-3-ol compound


Formula (13)



42-O-(tetrahydropyran-3-yl) rapamycin (Merilimus-3)

## 7. 42-O-(2H-Pyran-3-ol, tetrahydro-6-methoxy-2-methyl) compound


Formula (14)



42-O-(2H-Pyran-3-yl, tetrahydro-6-methoxy-2-methyl) rapamycin

## 8. 2H-Pyran-3-ol, tetrahydro-2,2-dimethyl-6-phenyl- compound

Formula (15)



42-O-(2H-Pyran-3-yl, tetrahydro-2,2-dimethyl-6-phenyl) rapamycin

In another embodiment, the invention describes the processes for 42-O-(tetrahydrofuran-3-yl) rapamycin compounds.


According to the process of the present invention, the starting reactant rapamycin of formula (2) is reacted with trifluoromethanesulfonic anhydride of formula (3) using an organic base of pyridine derivative of formula (4) as catalyst and in the presence of an halogenated organic solvent to obtain triflate intermediate of formula (5). This intermediate is further subjected to displacement reaction with 4, 5 or 6 membered 3-hydroxy heteroalkoxyalkyl compound of formula (6a), (6b) or (6c) in presence of a trialkyl amine of formula (7) and halogenated organic solvent to obtain 42-O-(heteroalkoxyalkyl) rapamycin compounds of general formula (1), which are separated and passed through two stages of column purification process to get purified compounds (8-15). Purified 42-O-(heteroalkoxyalkyl) rapamycin compounds (8-15) thus obtained are observed to be somewhat unstable at room temperature and therefore the same are stabilized by addition of phenolic anti-oxidants in acetone, such as BHT (2,6-di-t-butyl-4-

methylphenol, Butylated hydroxy toluene). This homogenous mixture is then isolated and dried by lyophilisation to get final solid derivative.

The formulae, definitions and detailed description for the related reactants, base, solvent and products are further described as follows:

### Rapamycin


Rapamycin as used herein is a starting reactant having structure presented by the following formula:



### Alkyl triflate

A method according to present invention, wherein said alkyl triflate is trifluoromethanesulfonic anhydride.

Formula (3)




Trifluoromethanesulfonic (Triflic) anhydride

This renders high stability, high activity and sound tractability to be beneficial for the reaction of the present invention. It can be stored at room temperature.


**Organic base**

The organic base is used as catalyst and may be selected from pyridine derivatives of formula (4).



Wherein R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are each individually selected from hydrogen and C<sub>1</sub>-C<sub>10</sub> alkyl substitutions.


A method according to present invention, wherein said pyridine derivative is 2, 6-dimethyl pyridine.

**Organic solvent**

The organic solvent may be selected from alkyl halide and other suitable inert halogenated organic solvents selected from ethylene chloride, methylene chloride, chlorobenzene or chloroform.

**Triflate intermediate**

Formula (5)




42-O-(trifluoromethylsulfonyl) rapamycin

Wherein trifluoromethane sulfonic anhydride is selected for the preparation of the triflate group, which is then reacted with a molecule of 3-hydroxy heteroalkoxyalkyl compounds of formula (6a), (6b) and (6c) to obtain 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula (1), wherein R is selected from the 4, 5 and 6 membered 3-hydroxy heteroalkoxyalkyl compounds of formula (6a), (6b) and (6c) as shown below:


#### 4 Membered ring

Formula (6a)




**5 Membered ring**

Formula (6b)




Tetrahydrofuran-3-ol




or

3-Furanol, tetrahydro-4-methyl-



or

3-Furanol, tetrahydro-2,5,5-trimethyl-




or

3-Furanol, Tetrahydro-2, 5-Diethyl-2-Methyl-


**6 Membered ring**

Formula (6c)




Tetrahydropyran-3-ol

18




or 2H-Pyran-3-ol, tetrahydro-6-methoxy-2-methyl-




or 2H-Pyran-3-ol, tetrahydro-2, 2-dimethyl-6-phenyl-

### Trialkyl amine


Formula (7)



Wherein  $R_1$ ,  $R_2$  and  $R_3$  are each selected from  $C_1 \sim C_{10}$  alkyl substituents respectively, A method according to present invention, said trialkyl amine is *N,N*-Di-isopropylethylamine or *N,N*-Di-*n*-butylethylamine.



*N,N*-Di-isopropylethylamine




or *N,N*-Di-*n*-butylethylamine

The compounds of 42-O-(heteroalkoxyalkyl) rapamycin encompass formulas (8) to (15).

Tetrahydrofuran-3-ol compound

Formula (8)




42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1)

Referring to the above compound (8), wherein the hydroxyl group at carbon number 42 in the rapamycin is modified with a moiety of tetrahydrofuran-3-ol compound.

4-methyl, tetrahydrofuran-3-ol compound

Formula (9)




42-O-(4-methyl, tetrahydrofuran-3-yl) rapamycin

Referring to the above compound (9), wherein the hydroxyl group at carbon number 42 in the rapamycin is modified with a moiety of 4-methyl, tetrahydrofuran-3-ol compound.

2,5,5-trimethyl, tetrahydrofuran-3-ol compound

Formula (10)




42-O-(2,5,5-trimethyl, tetrahydrofuran-3-yl) rapamycin

Referring to the above compound (10), wherein the hydroxyl group at carbon number 42 in the rapamycin is modified with a moiety of 2,5,5-trimethyl, tetrahydrofuran-3-ol compound.

2,5-diethyl-2-methyl, tetrahydrofuran-3-ol compound

Formula (11)




42-O-(2,5-diethyl-2-methyl, tetrahydrofuran-3-yl) rapamycin

Referring to the above compound (11), wherein the hydroxyl group at carbon number 42 in the rapamycin compound is modified with a moiety of 2,5-diethyl-2-methyl, tetrahydrofuran-3-ol compound.

Oxetan-3-ol compound

Formula (12)




42-O-(oxetan-3-yl) rapamycin (Merilimus-2)

Referring to the above compound (12), wherein the hydroxyl group at carbon number 42 in the rapamycin compound is modified with a moiety of Oxetan-3-ol compound.

Tetrahydropyran-3-ol compound

Formula (13)




42-O-(tetrahydropyran-3-yl) rapamycin (Merilimus-3)

Referring to the above compound (13), wherein the hydroxyl group at carbon number 42 in the rapamycin compound is modified with a moiety of tetrahydropyran-3-ol compound.

42-O-(2H-Pyran-3-yl, tetrahydro-6-methoxy-2-methyl) compound

Formula (14)




42-O-(2H-Pyran-3-yl, tetrahydro-6-methoxy-2-methyl) rapamycin

Referring to the above compound (14), wherein the hydroxyl group at carbon number 42 in the rapamycin compound is modified with a moiety of 2H-Pyran-3-yl, tetrahydro-6-methoxy-2-methyl compound.

2H-Pyran-3-ol, tetrahydro-2,2-dimethyl-6-phenyl- compound

Formula (15)



42-O-(2H-Pyran-3-yl, tetrahydro-2,2-dimethyl-6-phenyl) rapamycin

Referring to the above compound (15), wherein the hydroxyl group at carbon number 42 in the rapamycin compound is modified with a moiety of 2H-Pyran-3-ol, tetrahydro-2, 2-dimethyl-6-phenyl compound.

The rapamycin, 42-O-(heteroalkoxyalkyl) compounds of the invention are prepared in two reaction steps. In step-1, the 42-hydroxyl group of rapamycin is activated with alkyl triflate in presence of an organic base and inert organic solvent to form triflate intermediate. In the synthesis of triflate intermediate for 42-O-(heteroalkoxyalkyl) rapamycin compounds, the organic solvent is not specifically restricted to halogenated solvent as long as it dissolves the starting materials and the reaction products.

In the synthesis of triflate intermediate for 42-O-(heteroalkoxyalkyl) rapamycin compound, the organic solvent should be used in an amount not less than 15 parts by weight; preferably 15 to 20 parts by weight, for 1 part by weight of rapamycin.

Accordingly, rapamycin, 42-O-(trifluoromethylsulfonyl) having a leaving group (triflate intermediate) is readily prepared by reaction of dry rapamycin with corresponding

trifluoromethylsulfonic anhydride, in the presence of inert methylene chloride and 2, 6-lutidine as catalyst under cooled temperature conditions and inert nitrogen gas environment. In the synthesis of triflate intermediate for 42-O-(heteroalkoxyalkyl) rapamycin compounds by the process according to the present invention, the trifluoromethanesulfonic (triflic) anhydride should be used in an amount not less than 3 mol, preferably 3 to 7 mol, per mol of rapamycin.

In the synthesis of triflate intermediate for 42-O-(heteroalkoxyalkyl) rapamycin compounds by the process according to the present invention, the 2, 6-Lutidine should be used in an amount not less than 6 mol, preferably 6 to 10 mol, per mol of rapamycin. The 2, 6-lutidine is added in the reaction to prevent an increase in the acidity of the reaction mixture, as during the reaction, the activating agent trifluoromethylsulfonic anhydride forms trifluoromethanesulfonic acid. Thus 2, 6-lutidine acts as an acid scavenger in order to move the reaction in forward direction. In the synthesis of triflate intermediate, the reaction temperature is -10 to -60 °C, preferably being -20 to -40 °C temperature.

In the synthesis of triflate intermediate for 42-O-(heteroalkoxyalkyl) rapamycin compounds, after addition of trifluoromethanesulfonic (triflic) anhydride; the reaction mixture is allowed to warm to -20 to 10 °C temperature, preferably at -20 to 0°C temperature.

In the synthesis of triflate intermediate for 42-O-(heteroalkoxyalkyl) rapamycin compounds, the reaction mixture is stirred to 10 to 80 minutes, preferably being 20 to 40 minutes to get pale yellow viscous mass.

In step-2, 42-O-(heteroalkoxyalkyl) rapamycin compound is prepared by displacement of the leaving group with the 3-hydroxy heteroalkoxyalkyl compound in presence of suitable trialkyl amine catalyst, selected from N,N-Di-n-butylethylamine or N,N Di-isopropylethylamine.

In the synthesis of 42-O-(heteroalkoxyalkyl) rapamycin compounds from triflate intermediate, N, N-di-isopropylethylamine or N, N-Di-n-butylethylamine should be used in an amount not less than 10 mol, preferably 10 to 15 mol, per mol of rapamycin.

In the synthesis of 42-O-(heteroalkoxyalkyl) rapamycin compounds from triflate intermediate, after displacement with 3-hydroxy heteroalkoxyalkyl compound; the reaction mixture is allowed to warm to -20 to 10 °C temperature, preferably at -10 to 10 °C temperature.

In the synthesis of 42-O-(heteroalkoxyalkyl) rapamycin compounds from triflate intermediate, after displacement with 3-hydroxy heteroalkoxyalkyl compound; the reaction mixture is stirred to 12 to 96 hours, preferably being 36 to 60 hours at 5 to 35 °C temperature, preferably at 10 to 25 °C temperature.

The 3-hydroxy heteroalkoxyalkyl compounds are selected for the purpose of the present invention are among the products readily available commercially such as Oxetan-3-ol, Tetrahydrofuran-3-ol, Tetrahydro-4-methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2, 5-diethyl-2-methyl furan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol, Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol, etc.

The crude 42-O-(heteroalkoxyalkyl) rapamycin compound obtained according to the reactions as explained above is concentrated by evaporation under reduced pressure to provide a pale yellow viscous mass, which is purified and isolated in a conventional manner like extraction, precipitation, fractional crystallization, recrystallization, chromatography, and the like.

In all the embodiments, the desired 42-O-(heteroalkoxyalkyl) rapamycin compounds are easily separated from the side products preferably by two purification stages, such as preparative HPLC and combiflash column chromatography methods.

Since the purified 42-O-(heteroalkoxyalkyl) rapamycin compound is a polyene macrolide, which has a tendency to oxidize and decompose during the storage or handling. Therefore, to enhance the stability, a proper antioxidant in acetone is mixed with the concentrated 42-O-(heteroalkoxyalkyl) rapamycin compound before proceeding to isolation and drying steps.

The suitable antioxidants may be selected from; Butylated hydroxytoluene (BHT), DL- $\alpha$ -tocopherol, propyl gallate, ascorbyl palmitate, 3-tert-butyl-4-hydroxyanisole, 2-tert-butyl-4-hydroxyanisole, and fumaric acid.

The 3,5-di-tert-4-butyl hydroxy toluene (BHT) is the most preferable antioxidant adapted for use in the present invention.

The homogeneous reaction mixture obtained according to process as explained above is finally isolated and dried to obtain the 42-O-(heteroalkoxyalkyl) rapamycin compound of the present invention with an isolated good yield.

The purified 42-O-(heteroalkoxyalkyl) rapamycin compound is a white powder and it can be easily used for coating of medical device, handling, storage and stability.

The purified 42-O-(heteroalkoxyalkyl) rapamycin compounds thus obtained is analysed and identified by spectral studies like Nuclear Magnetic Resonance (NMR), Mass Spectra (MS) and High Performance Liquid Chromatography (HPLC).

In yet another embodiment, the invention provides pharmaceutical compositions comprising 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 in association with one or more pharmaceutical carrier/excipients. The pharmaceutical compositions incorporating a 42-O-(heteroalkoxyalkyl) rapamycin compounds can be prepared into various formulations for achieving desired therapeutic/clinical effect. Methods of making such formulations are well known in the art, where the active ingredient is mixed with suitable pharmaceutical excipient/carrier/substrate to yield desired formulation suitable for oral, injectable, parenteral, local administration or coating on implantable medical devices. The pharmaceutical excipient/carrier used includes diluents, lubricants, binders, emulsifiers, disintegrators, effervescent mixtures, adsorbents, colors, flavors, and sweeteners etc. The diluents are selected from lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycerol etc. The lubricants are selected from silicic acid, talc, stearic acid, or salts thereof such as calcium or magnesium stearate, polyethylene glycol, etc. The binders are selected from magnesium aluminum silicate, starches such as corn, wheat or rice starch, gelatin, methylcellulose, carboxymethyl cellulose, polyvinyl pyrrolidone etc. The disintegrators are selected from starches, agar, alginic acid, or its sodium salt etc.

Examples of typical formulations for coating on medical devices like coronary or other vascular stents are described herein below. It is understood that other compositions of

formulations are also possible and one should not assume that these are the only possible formulations of the compounds of formula 1.

The compositions described below can be used for vascular treatment specifically to prevent arterial restenosis. Formulation containing nano size particles can also be used for administration by parenteral or oral route or through direct delivery to the site of disease by implanting a medical device, such as a stent or balloon catheter; where the drug is coated on either the stent or on the balloon of the catheter.

The substrate/carrier/excipient particles serve to bind the 42-O-(heteroalkoxyalkyl) rapamycin compounds and to control the release rate of drug from the formulation. The formulation can optionally be converted into nanoparticles. Suitable substrates are lipid/s or biodegradable/non-degradable polymer/s and nano particles thereof. These substrates are safe and have history of usage in the systemic circulation.

Substrates suitable for formulation are numerous and varied; the general selection criterion being a substrate capable of carrying a 42-O-(heteroalkoxyalkyl) rapamycin compounds.

The biodegradable polymer substrates may include, but are not limited to poly lactide, poly glycolide, poly (lactide-co-glycolide), poly(glycolic acid-co-trimethylene carbonate), poly caprolactone, polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), ethylene vinyl alcohol, poly(hydroxyvalerate), poly(hydroxybutyrate); poly(hydroxybutyrate-co-valerate), polydioxanone; polyorthoester; polyanhydride and mixtures thereof. The non-degradable polymer substrates may include, but are not limited to polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acrylonitrilestyrene copolymers, cellulose; cellulose acetate; cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose

nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose, polyamides, such as Nylon 66 and polycaprolactam and mixtures thereof.

Lipid substrates may include, but are not limited to hydrogenated castor oil, hydrogenated palm oil, hydrogenated soybean oil, hydrogenated cottonseed oil, hydrogenated peanut oil, hydrogenated coconut oil, hydrogenated Turkish red oil, hydrogenated olive oil, hydrogenated isobutene oil and mixtures thereof.

In another embodiment, the invention provides a method of treating hyperproliferative vascular disease selected from the group consisting of restenosis and vascular occlusion in a mammal by administering an antiproliferative effective amount of 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 in association with one or more pharmaceutical carriers to said mammal orally, parenterally, intravascularly, or via an implantable medical device coated with the vascular stent impregnated with 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1. The restenosis, and vascular occlusion in a mammal may be caused due to infectious or a metabolic disorder.

In a further embodiment, the invention provides method of preventing or treating restenosis in a mammal by implanting a medical device coated with an effective amount of 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 in association with one or more pharmaceutical carriers.

In a further embodiment, the invention provides use of 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 for the preparation of medicament for the treatment of hyperproliferative vascular disease.

In a further embodiment, the invention provides use of 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 for coating on implantable medical device for the treatment of arterial restenosis.

A biocompatibility study of 42-O-(tetrahydrofuran-3-yl) rapamycin and 42-O-(oxetan-3-yl) rapamycin compounds are tested in-vitro. The testing details for cytotoxicity, haemolysis and haemocompatibility study are described in Example-3 and the results are shown in Table 3a, 3b, 3c<sub>1</sub> and 3c<sub>2</sub>.

Potency study of 42-O-(tetrahydrofuran-3-yl) rapamycin and 42-O-(oxetan-3-yl) rapamycin compounds are tested in-vitro and compared to the potency of parent molecule, rapamycin. The testing procedure is described in Example-4 and the results are shown in FIG 3a and 3b.

The process of 42-O-(heteroalkoxyalkyl) rapamycin compounds will be better understood in connection with the synthetic method of the present invention.

The following examples, which include preferred embodiments, will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purpose of illustrative discussion of preferred embodiments of the invention.

## **EXAMPLES**

### **EXAMPLE 1**

The process for efficient production of 42-O-(heteroalkoxyalkyl) rapamycin compounds in accordance with the present invention will be described in detail in view of the following examples:


#### **EXAMPLE 1A**

##### **STEP 1: Conversion of 42-O hydroxy of rapamycin to a trifluoromethanesulfonate leaving group:**

In a round bottom reaction flask (100ml, flame dried) equipped with magnetic stirrer, 4.2 grams (4.6mmol) of dried rapamycin, 2.95 grams (27mmol) 2, 6-dimethyl pyridine and 42ml dichloromethane were added. The reaction mixture was degassed and purged the nitrogen gas into the flask and stirred.

The reaction mixture in the flask was then cooled to -30° C temperature in acetonitrile-dry ice bath, and was slowly dripped therein with 3.96 grams (13.8 mmol) trifluoromethane sulfonic (triflic) anhydride in 10 ml dichloromethane under agitation. After dripping, the reaction solution was allowed to warm to -10 °C temperatures and stirred between -10 to 0° C temperature for 30 minutes to get triflate intermediate for step-1. The reaction

mixture became a pale yellow viscous mass. HPLC analysis indicated no residual rapamycin remained, which indicated completion of the reaction.




$C_{51}H_{79}NO_{13}$

Mol. Wt.: 914.17

Rapamycin

2,6-Lutidine,  $-30^{\circ}C$  to  $0^{\circ}C$ .  
 $Tf_2O$ ,  $CH_2Cl_2$



$C_{52}H_{78}F_3NO_{15}S$

Mol. Wt.: 1046.23

Triflate Intermediate

### REACTION SCHEME-A


**EXAMPLE 1B**

**STEP 2: Displacement of the leaving group with 5 membered 3-hydroxyheteroalkoxyalkyl compounds to synthesize 42-O-(heteroalkoxyalkyl) rapamycin compound**


**Preparation of 42-O-(tetrahydrofuran-3-yl), rapamycin (Merilimus 1)**

A reaction flask, containing triflate intermediate of step-1 was again cooled to -30° C temperature and 5.94 grams (46mmol) of N, N-Diisopropylethylamine (DIPEA) followed by 1.2 grams (13.8mmol) of tetrahydrofuran-3-ol compound in methylene chloride were added. The reaction mixture was stirred at 0° C temperature for 12 hours. The reaction mixture was then allowed to warm to 25 °C temperature and continuously stirred for 48 hours.


The reaction mixture was further concentrated by evaporation under reduced pressure to provide a pale yellow viscous mass. The quantitative HPLC of reaction mass shows theoretical yield of 68%. This mass was purified by preparative HPLC (MeOH (65%): ACN (15%): H<sub>2</sub>O (20%)) to obtain desired product in about 70% purity. Further purification was done by combiflash (0-40% EtOAc in Hexane) to get 42-O-(tetrahydrofuran-3-ol) rapamycin compound having 98.6% purity by HPLC. Then stabilizing agent BHT in acetone was homogeneously mixed with this purified compound and isolation & drying steps were carried out to get white solid powder of 42-O-(tetrahydrofuran-3-ol) rapamycin compound.



Triflate Intermediate



1. Two Stage of HPLC Column Purification
2. Isolation & Drying



$C_{55}H_{85}NO_{14}$

Mol Wt.: 984.29

Merilimus-1

**REACTION SCHEME-B**

The 42-O-(tetrahydrofuran-3-ol) rapamycin compound thus obtained was analytically identified.



#### **EXAMPLE 1C**

**STEP 2: Displacement of the leaving group with 4 membered 3-hydroxy heteroalkoxyalkyl compound to synthesize 42-O-(heteroalkoxyalkyl) rapamycin compound.**

##### **Preparation of 42-O-(oxetan-3-yl) rapamycin (Merilimus 2)**

A reaction flask containing triflate intermediate of step-1 was again cooled to -30° C temperature and 5.94 grams (46mmol) of N, N-Di-isopropylethylamine (DIPEA) followed by 1.25 grams (13.8mmol) of Oxetan-3-ol compound in methylene chloride were added. The reaction mixture was stirred at 0° C temperature for 12 hours. The reaction mixture was then allowed to warm to 25° C temperature and continuously stirred for 48 hours.

The reaction mixture was further concentrated by evaporation under reduced pressure to provide a pale yellow viscous mass. The quantitative HPLC of reaction mass shows theoretical yield of 71%. This mass was purified by preparative HPLC (MeOH (65%): ACN (15%): H<sub>2</sub>O (20%)) method to obtain desired product in about 75% purity. Further purification was done by combiflash (0-40% EtOAc in Hexane) to get 42-O-(oxatane-3-yl) rapamycin compound having 97.7% purity by HPLC. Then stabilizing agent BHT in acetone was homogeneously mixed with purified compound and isolation & drying steps were carried out to get white solid powder of 42-O-(oxatane-3-yl) rapamycin compound.

**REACTION SCHEME-C**

The 42-O-(oxatan-3-yl) rapamycin compound thus obtained was analytically identified.



**EXAMPLE 1D**

**STEP 2: Displacement of the leaving group with 6 membered 3-hydroxyheteroalkoxyalkyl compounds for the synthesis of 42-O-(heteroalkoxyalkyl) rapamycin compound.**

**Preparation of 42-O-(tetrahydropyran-3-yl), rapamycin (Merilimus 3)**

A reaction flask containing triflate intermediate of step-1 was further cooled to -50° C temperature and 6.07 grams (46mmol) of N,N-di-n-butylethylamine (DNBEA) followed by 1.17 grams (13.8mmol) of tetrahydropyran-3-ol compound in methylene chloride were added. The reaction mixture was stirred at -10° C temperature for 12 hours. The reaction mixture was then allowed to warm to 15° C temperature and continuously stirred for 48 hours.

The reaction mixture was further concentrated by evaporation under reduced pressure to provide a pale yellow viscous mass. The quantitative HPLC of reaction mass shows theoretical yield of 62%. This mass was purified by preparative HPLC (MeOH (65%): ACN (15%): H<sub>2</sub>O (20%)) to obtain the desired product in about 65% purity. Further purification was done by combiflash (0-40% EtOAc in Hexane) to get 42-O-(tetrahydropyran-3-yl) rapamycin compound having 97.3% purity by HPLC. Then stabilizing agent BHT in acetone was homogeneously mixed with purified compound and isolation & drying steps were carried out to get white solid powder of 42-O-(tetrahydropyran-3-yl) rapamycin compound.



### REACTION SCHEME-D

The 42-O-(tetrahydropyran-3-yl) rapamycin compound thus obtained was analytically identified.

Similarly, other 42-O-(heteroalkoxyalkyl) rapamycin compounds of formulas (9), (10), (11), (14) and (15) were prepared by treating the triflate intermediate of step 1 with corresponding 3-hydroxy heteroalkoxyalkyl compound by employing the reaction procedure described in Step-2 of Example 1.

#### Characterization of 42-O-(heteroalkoxyalkyl) rapamycin compounds

42-O-(heteroalkoxyalkyl) rapamycin compounds obtained from four successive batches gave the following values on repeated analyses.

#### HPLC:

To check the purity of the 42-O-(heteroalkoxyalkyl) rapamycin compounds the following condition was followed by using High Performance Liquid Chromatography, Phenomenex Synergi Hydro-RP 80a (250X 4.6) mm, 4 micron column. The mobile phase was 65:15:20 methanol:acetonitrile:water mixture. The detector was set at 276 nm and the flow rate was adjusted to 1.5 mL/min. Column temperature was 40° C. 2.0 µg of 42-O-(heteroalkoxyalkyl) rapamycin compounds was injected onto the column in a volume of 5.0 µL methanol with run time of 50 min.

Purity for 42-O-(tetrahydrofuran-3-yl), rapamycin (Merilimus-1) compound, 42-O-(oxatan-3-yl), rapamycin (Merilimus-2) compounds and 42-O-(tetrahydropyran-3-yl), rapamycin (Merilimus-3) compound were measured as 98.54%, 97.21% and 97.34% respectively (average of three runs; SD = 0.2).

Table 1


Chromatography method for measuring purity	
Column	: Phenomenex Synergi Hydro-RP 80a (250X 4.6) mm, 4 micron column
Eluent	: 65:15:20 methanol:acetonitrile:water mixture (by volume)
Flow	: 1.5 mL/min
Detection	: 276 nm
Column Temp.:	40 °C
Sample Vol.	: 2.0µg injected in a 5.0µL methanol
Run Time	: 50 min

### Spectral Studies:

The <sup>1</sup>H-NMR studies are conducted for the starting material rapamycin and its heteroalkoxyalkyl compounds. On comparison, it is found that there are additional proton peaks corresponding to heteroalkoxyalkyl compounds clearly identified and the studies of few compounds of 42-O-(heteroalkoxyalkyl) rapamycin are discussed below.

#### 1) 42-O-(tetrahydrofuran-3-yl), rapamycin (Merilimus-1) compound


I) The protons at 4.3 ppm which corresponds to one proton (tetrahydrofuran ring)



O C-42-Rapamycin derivative

attached to oxygen of rapamycin.

II) The other two methylene ether linked protons (4 protons) identified at around 3.7 to



3.9 ppm. O C-42-Rapamycin derivative

III) The methylene 2 protons are identified at around 1.7 ppm (merged with other peaks).




O C-42-Rapamycin derivative


The above mentioned (point I, II & III) H-NMR data clearly shows the tetrahydrofuran ring is attached to the rapamycin. The rest of the peaks are identical to rapamycin.

## 2) 42-O-(oxatan-3-yl), rapamycin (Merilimus-2) compound

I) The protons at 4.3 ppm which corresponds to one proton (oxatan ring) attached to




II) The other two methylene ether linked protons (4 protons) identified at around 3.6 to




The above mentioned (point I & II) H-NMR data clearly shows the oxatan ring is attached to the rapamycin. The rest of the peaks are identical to rapamycin.

## 3) 42-O-(tetrahydropyran-3-yl), rapamycin (Merilimus-3) compound


I) The protons at 4.3 ppm which corresponds to one proton (tetrahydropyran ring)



II) The other two methylene ether linked protons (4 protons,) identified at around 3.5 to



III) The two methylene 4 protons are identified at around 1.7 to 2.0 ppm (merged with



The above mentioned (point I, II & III) H-NMR data clearly shows the tetrahydropyran ring is attached to the rapamycin. The rest of the peaks are identical to rapamycin.

The various chemical structures of 42-O-(heteroalkoxyalkyl) rapamycin compounds are further verified by LC Mass Spectrometric ION TRAP analysis. The results are consistent with all the chemical structures of 42-O-(heteroalkoxyalkyl) rapamycin compounds.

The m/z peaks for 42-O-(tetrahydrofuran-3-yl), rapamycin (Merilimus-1, C<sub>55</sub>H<sub>85</sub>NO<sub>14</sub>) compound, 42-O-(oxatan-3-yl), rapamycin (Merilimus-2, C<sub>54</sub>H<sub>83</sub>NO<sub>14</sub>) compound and 42-O-(tetrahydropyran-3-yl), rapamycin (Merilimus-3, C<sub>56</sub>H<sub>87</sub>NO<sub>14</sub>) compound are observed at 984.13, 970.20 and 998.18 respectively; which further confirmed the structure of 42-O-(heteroalkoxyalkyl) rapamycin compounds of the present invention.

## **EXAMPLE 2**

### **Stability analysis of various 42-O-(heteroalkoxyalkyl) rapamycin compounds.**

All the 42-O-(heteroalkoxyalkyl) rapamycin compounds prepared by this method are unstable and hence decreases their purity over a time period. The purity loss was higher at increased temperature, but there was no apparent change in the impurity profile. Table 2A presents the purity of various 42-O-(heteroalkoxyalkyl) rapamycin compounds at different time intervals and temperature conditions. Examples describe that even in a sealed container at 25 °C temperature, purity of 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) compound decreases from 98.7% to 94.1% over a period of 12 weeks, for 42-O-(oxetan-3-yl) rapamycin (Merilimus-2) compound decreases from 97.6% to 93.9% and for 42-O-(tetrahydropyran-3-yl) rapamycin (Merilimus-3) compound decreases from 97.6% to 93.5% over a period of 12 weeks. These losses of purity were increased in a sealed container when held at 40 °C versus kept at 25 °C temperature from 98.6% to 93.5% for Merilimus-1, from 97.3% to 92.7% for Merilimus-2 and from 97.5% to 91.6% for Merilimus-3 over just 12 weeks.

The inventors have also conducted the stability study of various 42-O-(heteroalkoxyalkyl) rapamycin compounds as mentioned above using various BHT concentrations. The study was conducted at 40° C temperature in sealed container for 8 weeks.

42-O-(heteroalkoxyalkyl) rapamycin compounds obtained as per procedure described in Example 1 are respectively added with anti-oxidant, namely Butylated Hydroxytoluene

(or BHT), at a concentration of 0.1%, 0.2%, 0.5%, and 1.0% (w/w) based on 100% (w/w) of 42-O-(heteroalkoxyalkyl) rapamycin compounds in sealed container to study the stability at 40° C temperature. Study outcome with various concentrations of BHT in Merilimus-1 and Merilimus-2 reveals that the loss in purity was significantly less i.e. 98.3% and 97.4% respectively even after eight-weeks of storage. But in case of 42-O-(tetrahydropyran-3-yl) rapamycin (Merilimus-3) compound the stability drastically reduced to 94.9% even at 1.0% BHT concentration. Comparatively, a control test is provided by adding 0.0% of anti-oxidant (BHT) into 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) compound, 42-O-(oxetan-3-yl) rapamycin (Merilimus-2) compound and 42-O-(tetrahydropyran-3-yl) rapamycin (Merilimus-3) compound resulting in a reduction of purity to 94.7%, 93.6% and 92.3% respectively after eight-weeks of storage. The purity data with the addition of different amounts of anti-oxidant as added to 42-O-(tetrahydrofuran-3-yl) rapamycin compound, 42-O-(oxetan-3-yl) rapamycin compound and 42-O-(tetrahydropyran-3-yl) rapamycin compound checked at different time intervals are summarized in Table 2B as below mentioned.

**Table 2A** Stability data of 42-O-(heteroalkoxyalkyl) rapamycin compounds without BHT at various temperatures

Time after Synthesis, weeks	Purity (%) of 42-O-(tetrahydrofuran-3-yl) rapamycin			
	5° C (sealed)	25° C (sealed)	25° C (unsealed)	40° C (sealed)
00	98.6	98.7	98.4	98.6
02	97.8	97.6	97.1	96.7
04	97.0	96.9	96.7	96.3
08	96.7	96.7	95.2	94.7
12	96.3	94.1	93.6	93.5
	Purity (%) of 42-O-(oxetan-3-yl) rapamycin			
00	97.7	97.6	97.3	97.3
02	96.5	96.2	95.9	95.5
04	95.6	95.1	94.8	94.6
08	94.8	94.5	94.0	93.6
12	94.2	93.9	93.6	92.7

<b>Purity (%) of 42-O-(tetrahydropyran-3-yl) rapamycin</b>				
00	97.3	97.6	97.0	97.5
02	96.0	95.7	95.3	94.4
04	95.4	95.2	94.5	93.7
08	94.5	94.6	93.8	92.3
12	93.9	93.5	93.1	91.6

**Table 2B** Stability results of 42-O-(heteroalkoxyalkyl) rapamycin compounds with various concentration of BHT at 40° C temperature.

<b>BHT (w/w)</b>	<b>Purity (%) of 42-O-(tetrahydrofuran-3-yl) rapamycin</b>			
	<b>0 week</b>	<b>2 weeks</b>	<b>4 weeks</b>	<b>8 weeks</b>
0.0%	98.6	96.7	96.3	94.7
0.1%	98.6	98.5	98.5	98.4
0.2%	98.5	98.5	98.5	98.4
0.5%	98.5	98.4	98.4	98.3
1.0%	98.5	98.4	98.4	98.3
<b>Purity (%) of 42-O-(oxetan-3-yl) rapamycin</b>				
0.0%	97.3	95.5	94.6	93.6
0.1%	97.7	97.5	97.5	97.5
0.2%	97.6	97.6	97.5	97.5
0.5%	97.6	97.5	97.4	97.4
1.0%	97.6	97.5	97.4	97.4
<b>Purity (%) of 42-O-(tetrahydropyran-3-yl) rapamycin</b>				
0.0%	97.5	94.4	93.7	92.3
0.1%	97.5	95.9	94.3	93.6
0.2%	97.6	96.3	95.6	94.1
0.5%	97.3	96.5	95.9	94.5
1.0%	97.4	96.6	95.6	94.9

The various stability study results indicated that steric hindrance plays a significant role in the stability of 42-O-(heteroalkoxyalkyl) rapamycin compounds. Comparing stability study outcome data of various 4-membered, 5-membered and 6-membered 42-O-(heteroalkoxyalkyl) rapamycin compounds the effect of steric hindrance reverses the

order of stability towards the 6-membered group and bulky molecule compounds. The stability data up to 8 weeks for all 42-O-(heteroalkoxyalkyl) rapamycin compounds including Merilimus-1, Merilimus-2 and Merilimus-3 without BHT and with 1.0% BHT at 40 °C temperature are shown in FIG. 2A and 2B respectively.

Thus these finding gives useful details on importance of antioxidant in maintaining the stability of 42-O-(heteroalkoxyalkyl) rapamycin compounds and further selection of more thermally stable 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) compound and 42-O-(oxetan-3-yl) rapamycin (Merilimus-2) compound for designing of biocompatibility test and anti-proliferative study.

### EXAMPLE 3

#### In-vitro Biocompatibility Tests of 42-O-(tetrahydrofuran-3-yl) rapamycin and 42-O-(oxetan-3-yl) rapamycin compounds

##### 3a. Cytotoxicity Test

In-vitro assessment was done to check the cytotoxic or necrotic potential of the 42-O-(tetrahydrofuran-3-yl) rapamycin and 42-O-(oxetan-3-yl) rapamycin compounds by extraction method. In this study extracts of test substance were kept in contact with a multiple culture of L-929 (ATCC cell lines CCL-1, NCTC clone 929) *Mus musculus* mouse fibroblast cells for 48 hours. The cells were examined microscopically to assess the changes for its general morphology, vacuolization, detachment, cell lysis and membrane integrity. The test results are shown in Table 3a.

**Table 3a**

Sample	Observation	Grade	Inference
Positive Control	Cells were rounded off their appendages were withdrawn. Nearly complete destruction of the cell layers.	3	Severely Cytotoxic
Negative Control	Cells were well in shape and morphology with no cell lysis.	0	Non-Cytotoxic
Test Sample	Cells were well in shape and morphology with no cell lysis.	0	Non-Cytotoxic

On the basis of cytotoxicity test findings the 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) compound and 42-O-(oxetan-3-yl) rapamycin (Merilimus-2) compound did not reveal any toxic effect on cells and both 42-O-(tetrahydrofuran-3-yl) rapamycin and 42-O-(oxetan-3-yl) rapamycin compounds met the requirement of the in-vitro cytotoxicity test.

### 3b. Haemolysis Test

Haemolysis test was conducted on rabbit blood by in-vitro method to check the haemolytic effect of 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) compound and 42-O-(oxetan-3-yl) rapamycin (Merilimus-2) compound. In this study the extracts of the test substances in triplicate were kept in contact with rabbit blood and incubated for 4 hrs. The concentration of plasma haemoglobin liberated in supernatant was calculated by comparing with absorbance of the standard solution in a spectrophotometer at 540nm. The haemolytic index was calculated by the standard formula and test results are summarised in Table 3b.

**Table 3b Haemoglobin Content in Supernatants**

Sample No.	(Merilimus-1)		(Merilimus-2)	
	Haemoglobin (mg/mL)	Haemolytic Index	Haemoglobin (mg/mL)	Haemolytic Index
Test (Extract) 1	0.34	1.7	0.40	2.0
Test (Extract) 2	0.39	1.9	0.39	1.9
Test (Extract) 3	0.28	1.4	0.39	1.9
Mean ± S. D.	0.34 ± 0.05	1.7 ± 0.02	0.39 ± 0.05	1.9 ± 0.02

Haemolytic index = Haemoglobin released (mg/ml)/Haemoglobin present (mg/ml) x 100

The Haemolytic index out come was 1.7 for 42-O-(tetrahydrofuran-3-yl) rapamycin compound and 1.9 for 42-O-(oxetan-3-yl) rapamycin compound extracts.

On the basis of haemolytic index results the 42-O-(tetrahydrofuran-3-yl) rapamycin compound and 42-O-(oxetan-3-yl) rapamycin compound show non-haemolytic natures and meet the requirement of the haemolysis test.



**Table 3d Haematological Findings for 42-O-(oxetan-3-yl) rapamycin compound**

S. No.	Parameters	Control			Test			Normal Range
		Rabbit No.			Rabbit No.			
		1	2	3	1	2	3	
1.	<b>Thrombosis</b>	Nil	Nil	Nil	Nil	Nil	Nil	Normal distribution No aggregation.
2.	<b>Coagulation</b> (PTT in sec.)	36	35	38	36	36	38	15.7-42.7
3.	<b>Platelet count</b> (in lakhs/cmm)	4.9	4.5	4.5	4.9	4.5	4.5	2.7-6.3
4 (a)	<b>Leucocyte count</b> (in Thousand/cmm)	7.4	6.9	7.2	7.5	6.5	7.5	5.2 - 12.5
(b)	<b><u>Differential</u></b>							
	Neutrophil %	55	49	45	53	48	48	20-75
	Lymphocyte %	42	48	52	44	50	49	30-85
	Eosinophil %	01	02	02	02	01	02	1-4
	Monocyte %	02	01	01	01	01	01	1-4
	Basophil %	00	00	00	00	00	00	
5.	<b><u>Distribution of cells</u></b>							
(a)	<b>RBC</b>	Normal	Normal	Normal	Normal	Normal	Normal	Normal
(b)	<b>WBC</b>	Normal	Normal	Normal	Normal	Normal	Normal	Normal
(c)	<b>Platelets</b>	Normal	Normal	Normal	Normal	Normal	Normal	Normal

On the basis of the above all haematological findings for 42-O-(tetrahydrofuran-3-yl) rapamycin and 42-O-(oxetan-3-yl) rapamycin compounds did not reveal any significant changes when compared to their corresponding control, as all the parameter fell within the range of normal limit. So the both the compounds 42-O-(tetrahydrofuran-3-yl) rapamycin and 42-O-(oxetan-3-yl) rapamycin compounds are haemocompatible and meet the requirement of the haemocompatibility test.

#### **EXAMPLE 4**

In-vitro Potency of 42-O-(oxetan-3-yl) rapamycin and 42-O-(tetrahydrofuran-3-yl) rapamycin compounds

In-vitro assessment of relative anti-proliferative effect of novel mTOR inhibitors 42-O-(oxetan-3-yl) rapamycin compound and 42-O-(tetrahydrofuran-3-yl) rapamycin compound with rapamycin was done on human and rabbit smooth muscle cell culture models. In which, human aorta and rabbit iliac artery smooth muscle cell cultures were subjected to increasing doses of 42-O-(oxetan-3-yl) rapamycin compound 42-O-(tetrahydrofuran-3-yl) rapamycin compound and rapamycin over 5 orders of magnitude concentration in the cell culture medium. The ability of the cell culture to reproduce was assessed after drug exposure by addition of a BromodeoxyUridine (BrdU) coloured reagent which causes a colour change in the surviving cells. The extent of colour development was quantified at 450nm wavelength using a spectrophotometer microplate reader (BMG Labtech, FLUOstar OPTIMA). Higher OD readings reflect an increased incorporation of BrdU into cellular DNA and therefore reflect more active proliferation. On the contrary, lower OD values reflect less incorporation on BrdU and a shift towards cell inhibition. Growth inhibition was calculated by subtracting positive control OD values, which represent 100% uninhibited growth.

The potency of 42-O-(oxetan-3-yl) rapamycin and 42-O-(tetrahydrofuran-3-yl) rapamycin compounds were tested in vitro and compared to the potency of rapamycin. The values of test results are shown in FIG 3A and FIG 3B.

The results summary illustrate that the 42-O-(oxetan-3-yl) rapamycin (Merilimus-2) compound and 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) compound have similar potency in growth suppression of both hAoSMCs and RbIASMCs smooth muscle cells over 5 orders of magnitude concentration. It was also observed that 42-O-(oxetan-3-yl) rapamycin and 42-O-(tetrahydrofuran-3-yl) rapamycin compounds of the present invention more effectively inhibited growth of smooth muscle cells than rapamycin.

#### **EXAMPLE 5**

Formulation using mixture of biodegradable polymers as substrate 80mg Poly L- lactide, 23mg Poly (lactide-co-glycolide) and 59mg 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) are dissolved in 50ml of methylene dichloride solvent to get clear transparent solution. The solution is then spray coated on to medical device surface. A top protective layer of quick release polymer like polyvinyl pyrrolidone may be optionally provided. The solvent may then be removed under vacuum.

**EXAMPLE 6**

Formulation using lipid as substrate 70mg hydrogenated castor oil and 47mg 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) are dissolved in 50ml of methylene dichloride solvent. This clear transparent solution is then spray coated on to medical device surface. A top protective layer of quick release polymer like polyvinyl pyrrolidone may be optionally provided. The solvent may then be removed under vacuum.

**EXAMPLE 7**

Formulation using mixture of biodegradable polymers nanoparticles as substrate 800mg Poly L-Lactide, 300mg Poly (Lactide-co-Glycolide) and 250mg 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) are dissolved in 25ml of methylene chloride. This solution is then gradually added in to 150ml aqueous solution of 650 mg Sodium Oleate and 250mg Vitamin E-TPGS under high speed stirring. This results into a stable suspension. The particle size is reduced further by giving multiple passes through High Pressure Homogenizer. The particle size obtained was between 50 and 250 nm.


**EXAMPLE 8**

Formulation using substrate of solid lipid nanoparticles 900mg hydrogenated castor oil and 225mg 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1) are dissolved in 15ml of methylene dichloride. This solution is then gradually added to 150ml aqueous solution of 500mg Poloxamer-188 and 150mg Vitamin E-TPGS under high speed stirring. This resulted into a stable solid drug-lipid suspension. The desired range of particle size was achieved by giving multiple passes through High Pressure Homogenizer. The particle size obtained was between 50 and 450 nm.

Similarly, pharmaceutical compositions for 42-O-(oxetan-3-yl) rapamycin (Merilimus-2) are prepared as described in Example 5, 6, 7 and 8.

**We claim,**

1. 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1



Wherein, R denotes 3, 4 and 5 membered 3-hydroxy heteroalkoxyalkyl compounds selected from Tetrahydrofuran-3-ol, Oxetan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-4-methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2,5-diethyl-2-methyl furan-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol.


2. The 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 according to claim 1, wherein said compound is selected from the group consisting of:
- 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1);
  - 42-O-(oxetan-3-yl) rapamycin (Merilimus-2);
  - 42-O-(tetrahydropyran-3-yl) rapamycin (Merilimus-3);
  - 42-O-(4-methyl, tetrahydrofuran-3-yl) rapamycin;
  - 42-O-(2,5,5-trimethyl, tetrahydrofuran-3-yl) rapamycin;
  - 42-O-(2,5-diethyl-2-methyl, tetrahydrofuran-3-yl) rapamycin;
  - 42-O-(2H-Pyran-3-yl, tetrahydro-6-methoxy-2-methyl) rapamycin and
  - 42-O-(2H-Pyran-3-yl, tetrahydro-2,2-dimethyl-6-phenyl) rapamycin.

3. The 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 according to claim 2, wherein said compound is 42-O-(tetrahydrofuran-3-yl) rapamycin (Merilimus-1).
4. The 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 according to claim 2, wherein said compound is 42-O-(oxetan-3-yl) rapamycin (Merilimus-2).
5. The 42-O-(heteroalkoxyalkyl) rapamycin compounds of formula 1 according to claim 2, wherein said compound is 42-O-(tetrahydropyran-3-yl) rapamycin (Merilimus-3).
6. A process for preparation of 42-O-(heteroalkoxyalkyl) rapamycin compounds represented by the general formula (1) comprising:
  - a) reacting rapamycin with triflic anhydride in presence of an organic base and halogenated organic solvent to obtain triflate intermediate; and
  - b) reacting the triflate intermediate with 4, 5 or 6- membered 3-hydroxy heteroalkoxyalkyl compound in presence of trialkyl amine and halogenated organic solvent to obtain 42-O-(heteroalkoxyalkyl) rapamycin compounds; and
  - c) purifying the 42-O-(heteroalkoxyalkyl) rapamycin compounds.
7. The process according to claim 6, wherein, the organic base is selected from pyridine or its derivatives and used in amount of 3 to 15 mol per mol of rapamycin.
8. The process according to claim 6, wherein said triflic anhydride is used in an amount of 1 to 10 mol per mol of the 42-O-(heteroalkoxyalkyl) rapamycin compound to obtain triflate intermediate of 42-O-(heteroalkoxyalkyl) rapamycin compound.
9. The process according to claim 6, wherein, the inert organic solvent is selected from halogenated organic solvent and used in amount of 10 to 30 parts by weight for 1 part by weight of rapamycin.
10. The process according to claim 6, wherein the trialkyl amine is selected from N, N-Di-isopropylethylamine or N, N-Di-n-butylethylamine and is used in the reaction in an amount of 5 to 20 mol per mol of rapamycin.


11. The process according to claim 6, wherein the 3-hydroxy heteroalkoxyalkyl compound is selected from Oxetan-3-ol, Tetrahydrofuran-3-ol, Tetrahydro-4-methyl furan-3-ol, Tetrahydro-2,5,5-trimethyl furan-3-ol, Tetrahydro-2, 5-diethyl-2-methyl furan-3-ol, Tetrahydropyran-3-ol, Tetrahydro-6-methoxy-2-methyl 2H-Pyran-3-ol and Tetrahydro-2,2-dimethyl-6-phenyl 2H-Pyran-3-ol and is used in the reaction amount of 1 to 7 mol per mol of rapamycin.
12. The process according to claim 6, wherein said purified 42-O-(heteroalkoxyalkyl) rapamycin compound is stabilized by the addition of an anti-oxidant for enhancing a storage stability.
13. The process according to claim 11, wherein the anti-oxidant is selected from Butylated hydroxytoluene (BHT), DL- $\alpha$ -tocopherol, propyl gallate, ascorbyl palmitate, 3-tert-butyl-4-hydroxyanisole, 2-tert-butyl-4-hydroxyanisole, and fumaric acid and is used between 0.1% to 1.0% (w/w) based on 100% (w/w) of 42-O-(heteroalkoxyalkyl) rapamycin compounds.
14. A pharmaceutical composition comprising a compound of formula 1 together with one or more pharmaceutical carriers administrable orally, parenterally, intravascularly, or via an implantable medical device.
15. The pharmaceutical composition according to claim 14, wherein said composition is formulated in the form of oral, injectable and implantable medical device forms.
16. The pharmaceutical composition according to claim 15, wherein said implantable medical devices are stent and balloon catheter.
17. A method of treating hyperproliferative vascular disease selected from the group consisting of restenosis and vascular occlusion in a mammal by administering compound of formula 1 in association with one or more pharmaceutical carriers to said subject orally, parenterally, intravascularly, or via an implantable medical device impregnated with the compound of Formula 1 in association with one or more pharmaceutical carriers.

18. The method of treating restenosis in a subject according to claim 17, comprising administering a compound of formula 1 in association with one or more pharmaceutical carriers.
19. The method of repairing vascular injury/inflammation in a subject according to claim 17 comprising administering a compound of formula 1 in association with one or more pharmaceutical carriers.
20. Use of compounds of formula 1 for the preparation of medicament for the treatment of hyperproliferative vascular disease.


Fig 1A




1B



2A



2B



INTERNATIONAL SEARCH REPORT

International application No  
PCT/IN2011/000508

A. CLASSIFICATION OF SUBJECT MATTER  
INV. C07D498/18 A61K31/436 A61P41/00  
ADD.  
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
Minimum documentation searched (classification system followed by classification symbols)  
C07D A61K A61P  
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 151 413 A (CAUFIELD ET. AL.) 29 September 1992 (1992-09-29) column 1, line 35 - line 45; claims -----	1-20
Y	US 2005/101624 A1 (BETTS ET. AL.) 12 May 2005 (2005-05-12) paragraph [0007] - paragraph [0008]; claims; examples -----	1-20
Y	US 5 362 718 A (SKOTNICKI ET. AL.) 8 November 1994 (1994-11-08) column 6, line 46 - line 60; claims; examples -----	1-20
Y	WO 01/87372 A1 (CORDIS CORPORATION) 22 November 2001 (2001-11-22) claims; examples -----	1-20
	-/--	

Further documents are listed in the continuation of Box C.

See patent family annex.

\* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>
--	--

Date of the actual completion of the international search  20 December 2011	Date of mailing of the international search report  28/12/2011
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Helps, Ian

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/IN2011/000508

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 1 826 211 A1 (CORDIS CORPORATION) 29 August 2007 (2007-08-29) sentence 13; claims; figures 5,6 -----	1-20

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IN2011/000508

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5151413	A	29-09-1992	NONE
US 2005101624	A1	12-05-2005	AT 369372 T 15-08-2007 DE 602004008105 T2 30-04-2008 EP 1689754 A1 16-08-2006 HK 1097828 A1 28-03-2008 US 2005101624 A1 12-05-2005 US 2005131008 A1 16-06-2005 WO 2005047295 A1 26-05-2005
US 5362718	A	08-11-1994	AT 234307 T 15-03-2003 AT 350384 T 15-01-2007 AT 537176 T 15-12-2011 AU 679854 B2 10-07-1997 AU 2247495 A 10-11-1995 BR 9507323 A 30-09-1997 CA 2187024 A1 26-10-1995 CN 1149296 A 07-05-1997 CY 2378 B1 04-06-2004 CZ 9603052 A3 13-08-1997 DE 69529897 D1 17-04-2003 DE 69529897 T2 06-11-2003 DE 69535363 T2 19-04-2007 DE 122008000023 I1 14-08-2008 DK 763039 T3 05-05-2003 DK 1266899 T3 29-01-2007 EP 0763039 A1 19-03-1997 ES 2191704 T3 16-09-2003 ES 2277975 T3 01-08-2007 HK 1011352 A1 13-06-2003 HU 225915 B1 28-12-2007 IL 113179 A 15-06-1998 JP 3725901 B2 14-12-2005 JP H09512018 A 02-12-1997 LU 91438 A9 15-07-2008 LV 13038 B 20-10-2003 NL 300348 I1 01-07-2008 NZ 283988 A 28-07-1998 PL 316948 A1 17-02-1997 PT 763039 E 30-06-2003 PT 1266899 E 28-02-2007 RU 2134267 C1 10-08-1999 SK 133096 A3 09-04-1997 US 5362718 A 08-11-1994 WO 9528406 A1 26-10-1995 ZA 9503090 A 14-10-1996
WO 0187372	A1	22-11-2001	AT 298592 T 15-07-2005 AU 6158101 A 26-11-2001 AU 6295701 A 26-11-2001 AU 2001262957 B2 02-12-2004 BR 0110778 A 08-05-2007 CA 2408606 A1 22-11-2001 DE 60111743 D1 04-08-2005 DE 60111743 T2 15-12-2005 EP 1289576 A1 12-03-2003 ES 2244622 T3 16-12-2005 JP 2003533493 A 11-11-2003

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IN2011/000508

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
		MX PA02011099 A	19-08-2004	
		MX PA02011186 A	09-09-2004	
		PT 1289576 E	31-10-2005	
		US 8029561 B1	04-10-2011	
		WO 0187372 A1	22-11-2001	
-----				
EP 1826211	A1	29-08-2007	CA 2579734 A1	28-08-2007
			EP 1826211 A1	29-08-2007
			JP 2007262057 A	11-10-2007
			US 2007203172 A1	30-08-2007
-----				